Drug-Induced Parkinsonism: Causative Medications
Antipsychotic medications are the primary cause of drug-induced Parkinsonism, with high-potency typical antipsychotics like haloperidol carrying the greatest risk, though numerous other drug classes including calcium channel blockers, antiemetics, and antidepressants can also induce parkinsonian symptoms. 1, 2
Primary Offending Agents
Antipsychotic Medications (Highest Risk)
Typical (First-Generation) Antipsychotics:
- High-potency agents such as haloperidol produce the most extrapyramidal symptoms due to greater dopamine D2 receptor blockade 1
- Low-potency agents including thioridazine and chlorpromazine also cause parkinsonism, though they have more anticholinergic side effects 1
- Other typical antipsychotics: phenothiazines, butyrophenones, and thioxanthenes 3
- The risk is often dose-dependent and related to striatal dopamine D2 receptor occupancy 2
Atypical (Second-Generation) Antipsychotics:
- Carry lower risk compared to typical antipsychotics 2
- Aripiprazole, risperidone, and olanzapine can still induce parkinsonism 4, 5
- Quetiapine, clozapine, and pimavanserin are recognized as safer alternatives for patients with underlying Parkinson's disease 4
Antiemetic and Gastrointestinal Agents
Metoclopramide and benzamide derivatives are frequently implicated as "hidden neuroleptics" prescribed for nausea and vomiting 3
- Metoclopramide carries FDA warnings about extrapyramidal effects including drug-induced parkinsonism, akathisia, and tardive dyskinesia, with use beyond 12 weeks no longer recommended 6
- These peripheral dopaminergic antagonists accounted for 5% of reported cases in pharmacovigilance data 7
Calcium Channel Blockers
Flunarizine and cinnarizine are particularly problematic 3, 8
- These piperazine derivatives can cause a permanent nonprogressive parkinsonian syndrome even after drug discontinuation in elderly patients, fulfilling criteria for tardive parkinsonism 8
- Calcium channel blockers accounted for 5% of drug-induced parkinsonism cases and showed a delayed onset, with 20% of cases appearing 12 months after drug introduction 7
Secondary Offending Agents
Antidepressants
- Selective serotonin reuptake inhibitors (SSRIs) including fluoxetine and paroxetine 7, 3
- Tricyclic antidepressants 9
- Accounted for 8% of reported drug-induced parkinsonism cases 7
Mood Stabilizers and Anticonvulsants
Cardiovascular Medications
Dopamine-Depleting Agents
Other Medications
Clinical Considerations
Time Course
Most cases (69%) occur within the first 3 months after drug introduction, primarily with central dopaminergic antagonists 7
- A second peak (20%) appears at 12 months, mainly caused by calcium channel blockers 7
Risk Factors
- Age 60-79 years represents the highest risk period 7
- Female gender (60% of cases) 7
- Polypharmacy and drug interactions 10, 7
- Genetic risk factors involved in idiopathic Parkinson's disease 10
Clinical Features
Rigidity is the most frequently reported symptom (78.7%), with all three cardinal symptoms (rigidity, tremor, bradykinesia) present in only 37.4% of cases 7
- Bilateral symptoms are more common than in idiopathic Parkinson's disease 3
- Resting tremor may be absent 3
- Often associated with tardive dyskinesias 3
Management Approach
Cessation of the offending agent is the primary treatment, with evolution favorable in 88.7% of cases after partial or complete drug withdrawal 7
- Mean recovery time is 3 months after drug discontinuation 2
- In 10% of cases, symptoms persist, suggesting unmasking of underlying idiopathic Parkinson's disease 2, 5
- There is no evidence of benefit for anticholinergics or levodopa in treating drug-induced parkinsonism 10
- If the medication cannot be withdrawn, switch to agents with lower risk of drug-induced parkinsonism 10, 11
Important Caveat
Early diagnosis and rapid withdrawal of the antipsychotic drug may improve the possibility of complete recovery 12, making vigilant monitoring essential in all patients receiving dopamine receptor-blocking agents 10, 11